Click image to view it in full size

Liquid biopsy will record rapid adoption in early cancer screening/detection. Industry participants are encouraged to foster innovation through precision technology. With the inception of early blood-based cancer screening assays and incremental progress in NGS bioinformatics, the oncology applications market holds immense potential. Strategic alliances between IVD manufacturers and clinical laboratories will lead to success if all stakeholders collaborate to develop scientifically, clinically, and commercially relevant CDx test strategies to ensure the launch of a well-timed assay. More interventional clinical trials will push liquid biopsies to widespread use. Developing an algorithm to combine the appropriate circulating biomarkers will anchor liquid biopsy technology to become rapid, reliable, and non-invasive decision-making tools in the non-oncology applications market.